Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.
Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.
复制标题
DOI:
10.3109/10428194.2014.897701
复制
发表时间:
2014-12
影响因子:
2.6
通讯作者:
van Besien K
中科院分区:
文献类型:
--
作者:
Petri CR;O'Donnell PH;Cao H;Artz AS;Stock W;Wickrema A;Hard M;van Besien K
We examined clofarabine pharmacokinetics and association with renal toxicity in 62 patients participating in a phase I–II study of clofarabine–melphalan–alemtuzumab conditioning for hematopoietic stem cell transplant (HSCT). Pharmacokinetic parameters, including clofarabine area under the concentration–time curve (AUC), maximum concentration and clearance, were measured, and patients were monitored for renal injury. All patients had normal pretreatment creatinine values, but over half (55%) experienced acute kidney injury (AKI) after clofarabine administration. Age was the strongest predictor of AKI, with older patients at greater risk (p = 0.002). Clofarabine AUC was higher in patients who developed AKI, and patients with the highest dose-normalized AUCs experienced the most severe grades of AKI (p = 0.01). Lower baseline renal function, even when normal, was associated with lower clofarabine clearance (p = 0.008). These data suggest that renal-adjustment of clofarabine dosing should be considered for older and at-risk patients even when renal function is ostensibly normal.
登录
查看更多内容
DOI:
10.1111/j.1467-9868.2010.00761.x
发表时间:
2011-01-01
影响因子:
5.8
作者:
Delaigle, Aurore;Hall, Peter;Jin, Jiashun
通讯作者:
Jin, Jiashun
影响因子:
4.1
作者:
Kintzel, Polly E.;Visser, James A.;Campbell, Alan D.
通讯作者:
Campbell, Alan D.
影响因子:
20.3
作者:
Faderl, Stefan;Ravandi, Farhad;Kantarjian, Hagop M.
通讯作者:
Kantarjian, Hagop M.
影响因子:
39.2
作者:
Levey, Andrew S.;Coresh, Josef;Van Lente, Frederick
通讯作者:
Van Lente, Frederick
影响因子:
6.2
作者:
Nabhan, Chadi;Davis, Nancy;Venugopal, Parameswaran
通讯作者:
Venugopal, Parameswaran